
BioVie Inc. (BIVI) Stock Ticker
BIVI right now
Market factors today
Unlock the full BIVI picture
About BioVie Inc.
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
BIVI stock facts
| Ticker symbol | BIVI |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $12.1M |
| CEO | Cuong Viet Do |
| Employees | 13 |
| Headquarters | Carson City, NV, US |
| IPO date | 2020-09-18 |
| Website | bioviepharma.com |
What you can see for BIVI on Tickr
Live BIVI price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the BIVI report.
Rankings
FAQ
What is the ticker symbol for BioVie Inc.?
The ticker symbol for BioVie Inc. is BIVI, listed on the NASDAQ Capital Market.
What is BIVI?
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally,…